Richard
K. Parrish II, MD
Kass MA, Heuer DK, Higginbotham EJ, Johnson CA, Keltner
JL, Miller JP, Parrish II RK, Wilson MR, Gordon MO; for the Ocular
Hypertension Treatment Study Group. The Ocular Hypertension Treatment
Study: A randomized trial determines that topical ocular hypotensive
medication delays or prevents the onset of primary open-angle
glaucoma. Arch Ophthalmol. 2002;120:701-713.
Gordon MO, Beiser JA, Brandt JD, Heuer DK, Higginbotham EJ, Johnson
CA, Keltner JL, Miller JP, Parrish II RK, Wilson MR, Kass MA;
for the Ocular Hypertension Treatment Study Group. The Ocular
Hypertension Treatment Study: Baseline factors that predict the
onset of primary open-angle glaucoma. Arch Ophthalmol.
2002;120:714-720.
Michael A. Kass, MD
Kass MA, Heuer DK, Higginbotham EJ, Johnson CA, Keltner
JL, Miller JP, Parrish II RK, Wilson MR, Gordon MO; for the Ocular
Hypertension Treatment Study Group. The Ocular Hypertension Treatment
Study: A randomized trial determines that topical ocular hypotensive
medication delays or prevents the onset of primary open-angle
glaucoma. Arch Ophthalmol. 2002;120:701-713.
Gordon MO, Beiser JA, Brandt JD, Heuer DK, Higginbotham EJ, Johnson
CA, Keltner JL, Miller JP, Parrish II RK, Wilson MR, Kass MA;
for the Ocular Hypertension Treatment Study Group. The Ocular
Hypertension Treatment Study: Baseline factors that predict the
onset of primary open-angle glaucoma. Arch Ophthalmol.
2002;120:714-720.
Donald L. Budenz, MD
Kass MA, Heuer DK, Higginbotham EJ, Johnson CA, Keltner JL,
Miller JP, Parrish II RK, Wilson MR, Gordon MO; for the Ocular
Hypertension Treatment Study Group. The Ocular Hypertension Treatment
Study: A randomized trial determines that topical ocular hypotensive
medication delays or prevents the onset of primary open-angle
glaucoma. Arch Ophthalmol. 2002;120:701-713.
Johnson CA, Keltner JL, Cello KE, Edwards M, Kass MA, Gordon MO,
Budenz DL, Gaasterland DE, Werner E; for the Ocular Hypertension
Treatment Study Group. Baseline visual field characteristics in
the Ocular Hypertension Treatment Study. Ophthalmol. 2002;109:432-437.
Feuer WJ, Parrish II RK, Schiffman JC, Anderson DR, Budenz DL,
Wells MC, Hess DJ, Kass MA, Gordon MO, and the Ocular Hypertension
Treatment Study Group. The Ocular Hypertension Treatment Study:
Reproducibility of cup/disk ratio measurements over time at an
optic disc reading center. Am J Ophthalmol. 2002;133(1):19-28.
M. Roy
Wilson, MD
Kass
MA, Heuer DK, Higginbotham EJ, Johnson CA, Keltner JL, Miller
JP, Parrish II RK, Wilson MR, Gordon MO; for the Ocular Hypertension
Treatment Study Group. The Ocular Hypertension Treatment Study:
A randomized trial determines that topical ocular hypotensive
medication delays or prevents the onset of primary open-angle
glaucoma. Arch Ophthalmol. 2002;120:701-713.
Gordon
MO, Beiser JA, Brandt JD, Heuer DK, Higginbotham EJ, Johnson CA,
Keltner JL, Miller JP, Parrish II RK, Wilson MR, Kass MA; for
the Ocular Hypertension Treatment Study Group. The Ocular Hypertension
Treatment Study: Baseline factors that predict the onset of primary
open-angle glaucoma. Arch Ophthalmol. 2002;120:714-720.
Brandt
JD, Beiser JA, Kass MA, Gordon MO, and the Ocular Hypertension
Treatment Study (OHTS) Group. Central corneal thickness in the
Ocular Hypertension Treatment Study (OHTS). Ophthalmol.
2001;108(10):1779-1788.
Wilson
MR, Martone J. Epidemiology of chronic open-angle glaucoma. In:
Ritch R, Shields MB, Krupin T, eds. The Glaucomas. 1st
ed. St. Louis, Mo: Mosby Year Book; 1996:753-768.
Paul Palmberg,
MD, PhD
AGIS
Investigators. The Advanced Glaucoma Intervention Study (AGIS)
7. The relationship between control of intraocular pressure and
visual field deterioration. Am J Ophthalmol. 2000;130(4):429-440.
Armaly
MF. Ocular pressure and visual fields: a 10 year follow-up study.
Arch Ophthalmol. 1969;81:25.
Bigger
JF. A comparison of patient compliance in treated vs untreated
ocular hypertension. Trans Am Acad Ophthalmol Otolaryngol.
1976;81(2):277-285.
Brandt
JD, Beiser JA, Kass MA, Gordon MO, and the Ocular Hypertension
Treatment Study (OHTS) Group. Central corneal thickness in the
Ocular Hypertension Treatment Study (OHTS). Ophthalmol.
2001;108(10):1779-1788.
Chandler
P. Long-term results in glaucoma therapy. Am J Ophthalmol.
1960;49:221-246.
Collaborative
Normal-Tension Study Group. Comparison of glaucomatous progression
between untreated patients with normal-tension glaucoma and patients
with therapeutically reduced intraocular pressure. Am J Ophthalmol.
1998;126(4):487-497.
Doughty
MJ, Zaman ML. Human corneal thickness and its impact on intraocular
pressure measures: a review and meta analysis approach. Surv
Ophthalmol. 2000;44(5):367-408.
Ehlers
N, Bramsen T, Sperling S. Applanation tonometry and central corneal
thickness. Acta Ophthalmol (Copenh). 1975;53(1):34-43.
Gordon
MO, Beiser JA, Brandt JD, Heuer DK, Higginbotham EJ, Johnson CA,
Keltner JL, Miller JP, Parrish II RK, Wilson MR, Kass MA; for
the Ocular Hypertension Treatment Study Group. The Ocular Hypertension
Treatment Study: Baseline factors that predict the onset of primary
open-angle glaucoma. Arch Ophthalmol. 2002;120:714-720.
Harwerth
RS, Carter-Dawson L, Shen F, Smith III EL, Crawford ML. Ganglion
cell losses underlying visual field defects from experimental
glaucoma. Invest Ophthalmol Vis Sci. 1999;40(10):2242-2250.
Kass
MA, Heuer DK, Higginbotham EJ, Johnson CA, Keltner JL, Miller
JP, Parrish II RK, Wilson MR, Gordon MO; for the Ocular Hypertension
Treatment Study Group. The Ocular Hypertension Treatment Study:
A randomized trial determines that topical ocular hypotensive
medication delays or prevents the onset of primary open-angle
glaucoma. Arch Ophthalmol. 2002;120:701-713.
Lichter
PR, Musch DC, Gillespie BW, Guire KE, Janz NK, Wren PA, Mills
RP; for the CIGTS Study Group. Interim clinical outcomes in the
Collaborative Initial Glaucoma Treatment Study comparing initial
treatment randomized to medications or surgery. Ophthalmol.
2001;108(11):1943-1953.
Quigley
HA, Enger C, Katz J, Sommer A, Scott R, Gilbert D. Risk factors
for the development of glaucomatous visual field loss in ocular
hypertension. Arch Ophthalmol. 1994;112(5):644-649.
Ritch
R, Shields MB, Krupin T. Chronic open-angle glaucoma: treatment
overview. In: Ritch R, Shields MB, Krupin T, eds. The Glaucomas.
2nd ed, Vol 3, St. Louis, Mo: Mosby Year Book; 1996:1507-1519.
Sommer
A, Tielsch JM, Katz J, Quigley HA, Gottsch JD, Javitt J, Singh
K. Relationship between intraocular pressure and primary open
angle glaucoma among white and black Americans. Arch Ophthalmol.
1991;109(8):1090-1095.
Whitacre
MM, Stein RA, Hassanein K. The effect of corneal thickness on
applanation tonometry. Am J Ophthalmol. 1993;115(5):592-596.
